202 related articles for article (PubMed ID: 27480386)
1. Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.
Khorashad JS; Tantravahi SK; Yan D; Mason CC; Qiao Y; Eiring AM; Gligorich K; Hein T; Pomicter AD; Reid AG; Kelley TW; Marth GT; O'Hare T; Deininger MW
Leukemia; 2016 Nov; 30(11):2275-2279. PubMed ID: 27480386
[No Abstract] [Full Text] [Related]
2. Isolated polyglobulia as an uncommon presentation of chronic myeloid leukaemia.
Fozza C; Bonfigli S; Longu F; Pardini S; Dore F
Blood Cells Mol Dis; 2016 Jan; 56(1):37. PubMed ID: 26603721
[No Abstract] [Full Text] [Related]
3. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
4. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
5. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
[TBL] [Abstract][Full Text] [Related]
6. Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib.
Carulli G; Baratè C; Marini A; Ottaviano V; Cervetti G; Fontanelli G; Guerrini F; Arici R; Guerri V; Di Paolo A; Polillo M; Ferreri MI; Galimberti S; Petrini M
Hematol Oncol; 2015 Dec; 33(4):250-2. PubMed ID: 25256816
[No Abstract] [Full Text] [Related]
7. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
[No Abstract] [Full Text] [Related]
8. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
Sazawal S; Chikkara S; Singh K; Chaubey R; Chandra D; Mishra P; Mahapatra M; Seth T; Saxena R
Ann Diagn Pathol; 2017 Apr; 27():24-27. PubMed ID: 28325357
[TBL] [Abstract][Full Text] [Related]
9. Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.
Klil-Drori AJ; Yin H; Azoulay L; Harnois M; Gratton MO; Busque L; Assouline SE;
Haematologica; 2019 Jul; 104(7):e293-e295. PubMed ID: 30630987
[No Abstract] [Full Text] [Related]
10. Aggregates of Pseudogaucher Cells in a Pediatric Patient With Chronic Myeloid Leukemia.
Roldán Galiacho V; Moreno Gamiz M; Echebarrria-Barona A
J Pediatr Hematol Oncol; 2021 Aug; 43(6):224-225. PubMed ID: 34054044
[No Abstract] [Full Text] [Related]
11. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
[No Abstract] [Full Text] [Related]
12. Racial Differences in Survival of Elderly Adults with Chronic Myeloid Leukemia Before and After the Introduction of Imatinib in the United States.
Shah BK; Uprety D
J Am Geriatr Soc; 2016 Apr; 64(4):887-9. PubMed ID: 27100589
[No Abstract] [Full Text] [Related]
13. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
Singh S; Sharma PK
Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
[TBL] [Abstract][Full Text] [Related]
14. Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
Angriman F; Gutierrez Acevedo MN; Rossi MS; Gimenez Conca AD; Otero V; Arbelbide JA; Michelángelo H
Turk J Haematol; 2015 Jun; 32(2):193-4. PubMed ID: 26316496
[No Abstract] [Full Text] [Related]
15. Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate.
Maral S; Bakanay SM; Yikilmaz AS; Dilek I
J Cancer Res Ther; 2018; 14(6):1431-1433. PubMed ID: 30488870
[TBL] [Abstract][Full Text] [Related]
16. Age, gender and efflux transporter activity influence imatinib efficacy in chronic myeloid leukemia patients.
Vasconcelos FC; Bonecker ST; de Souza PS; Scheiner MAM; Amaral N; Zalcberg I; Thuler LCS; Maia RC
Leuk Res; 2019 Jul; 82():33-35. PubMed ID: 31152921
[No Abstract] [Full Text] [Related]
17. Everything old is new again: the case for imatinib as frontline therapy in 2017.
Lee SG; Lipton JH
Clin Adv Hematol Oncol; 2017 Apr; 15(4):302-305. PubMed ID: 28591105
[No Abstract] [Full Text] [Related]
18. The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.
Raanani P
Acta Haematol; 2016; 135(3):131-2. PubMed ID: 26535978
[No Abstract] [Full Text] [Related]
19. Survival Pattern of Chronic Myeloid Leukemia in a Pediatric Population in the United States.
El-Fattah MA
J Pediatr Hematol Oncol; 2017 Mar; 39(2):159-160. PubMed ID: 27782928
[No Abstract] [Full Text] [Related]
20. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
Rostami G; Hamid M; Jalaeikhoo H
Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
